Download the full case story below.
General Prognostics (GPx) is a digital therapeutics company headquartered in Boston, USA. The company is on a mission to revolutionise blood tests. They are developing a service on mSafety that can deliver vital information to care providers about blood diagnostics without drawing blood. To do this, GPx is harnessing the correlation between digital biomarkers and underlying blood biomarkers. Powered by their proprietary algorithms, a wearable application can deliver information about blood without a physical blood test.
Pain-free and non-invasive
GPx wants to make blood test information more accessible. Around the world, people struggle with chronic conditions. To monitor these conditions effectively, doctors prescribe regular bloodwork. Algorithmic blood tests are not only the easy and convenient option to blood monitoring, but it also comes at a relatively low cost. By fast-tracking their service on mSafety, GPx is on their way to delivering value to the entire world.
For more insights, download the PDF about the General Prognostics story – and how mSafety is supporting the development of their Bloodless Blood Tests.
Included in the customer story: